• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALERE SAN DIEGO, INC. CONSULT HCG DIPSTICK TEST 5000 25T; VISUAL, PREGNANCY HCG, PRESCRIPTION USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALERE SAN DIEGO, INC. CONSULT HCG DIPSTICK TEST 5000 25T; VISUAL, PREGNANCY HCG, PRESCRIPTION USE Back to Search Results
Model Number FHC-101
Medical Device Problem Code False Positive Result (1227)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 08/22/2024
Type of Reportable Event Malfunction
Event or Problem Description
The customer reported receiving a total of 3 false positive results while using consult hcg dipstick tests on 3 patients.The customer reported the first patient tested positive for covid-19 and prior to administering a steroid treatment (4mg dexamethasone and 40mg depo-medrol injection), a pregnancy test was conducted.The patient provided a fresh urine sample that was dipped for 5 seconds.The results were read at 3 minutes and a faint false positive hcg result was observed.As a result of the positive hcg result, the steroid treatment was not provided.The customer reported the patient was stable.See mdr 2027969-2024-00178 and 2027969-2024-00179 for the second and third patients.
 
Additional Manufacturer Narrative
Current investigation findings: retained devices from the reported lot number were tested with hcg-negative clinical urine and low hcg (3miu/ml) concentration samples.The results were read at 3 and 4 minutes and all devices yielded valid negative results.No false positive results were observed during in-house testing.The case details were reviewed along with the complaint history for the reported issue and no indications of a systemic issue were identified.Manufacturing batch record review did not uncover any relevant non-conformances and found that the lot met quality control specifications.Review of the risk management report for this product found that the reported issue is within the risk profile for this device; no new hazard has been identified.A root cause could not be determined from the available information as the reported issue was not replicated during testing of retention product.Complaints are tracked and trended on a monthly basis.Per the package insert: - very low levels of hcg (less than 50 miu/ml) are present in urine specimen shortly after implantation.However, because a significant number of first trimester pregnancies terminate for natural reasons, a test result that is weakly positive should be confirmed by retesting with a first morning urine specimen collected 48 hours later.A number of conditions other than pregnancy, including trophoblastic disease and certain non-trophoblastic neoplasms including testicular tumors, prostate cancer, breast cancer, and lung cancer, cause elevated levels of hcg.Therefore, the presence of hcg in urine specimen should not be used to diagnosis pregnancy unless these conditions have been ruled out.This test provides a presumptive diagnosis for pregnancy.A confirmed pregnancy diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.
 
Event or Problem Description
The customer reported receiving a total of 3 false positive results while using consult hcg dipstick tests on 3 patients.The customer reported the first patient tested positive for covid-19 and prior to administering a steroid treatment (4mg dexamethasone and 40mg depo-medrol injection), a pregnancy test was conducted.The patient provided a fresh urine sample that was dipped for 5 seconds.The results were read at 3 minutes and a faint false positive hcg result was observed.As a result of the positive hcg result, the steroid treatment was not provided.The customer reported the patient was stable.See mdr 2027969-2024-00178 and 2027969-2024-00179 for the second and third patients.
 
Additional Manufacturer Narrative
D9 - date returned to mfg: was updated from blank to 10/28/2024.Retained and returned devices from the reported lot number were tested with hcg-negative clinical urine and low hcg (3miu/ml) concentration samples.The results were read at 3 and 4 minutes and all devices yielded valid negative results.No false positive results were observed during in-house testing.The case details were reviewed along with the complaint history for the reported issue and no indications of a systemic issue were identified.Manufacturing batch record review did not uncover any relevant non-conformances and found that the lot met quality control specifications.Review of the risk management report for this product found that the reported issue is within the risk profile for this device; no new hazard has been identified.A root cause could not be determined from the available information as the reported issue was not replicated during testing of retention or returned product.Complaints are tracked and trended on a monthly basis.Per the package insert: - very low levels of hcg (less than 50 miu/ml) are present in urine specimen shortly after implantation.However, because a significant number of first trimester pregnancies terminate for natural reasons, a test result that is weakly positive should be confirmed by retesting with a first morning urine specimen collected 48 hours later.- a number of conditions other than pregnancy, including trophoblastic disease and certain non-trophoblastic neoplasms including testicular tumors, prostate cancer, breast cancer, and lung cancer, cause elevated levels of hcg.Therefore, the presence of hcg in urine specimen should not be used to diagnosis pregnancy unless these conditions have been ruled out.- this test provides a presumptive diagnosis for pregnancy.A confirmed pregnancy diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CONSULT HCG DIPSTICK TEST 5000 25T
Common Device Name
VISUAL, PREGNANCY HCG, PRESCRIPTION USE
Manufacturer (Section D)
ALERE SAN DIEGO, INC.
9942 mesa rim rd
san diego CA 92121
Manufacturer Contact
monika burrell
9942 mesa rim rd
san diego, CA 92121
8588052506
MDR Report Key20509213
Report Number2027969-2024-00177
Device Sequence Number9170981
Product Code JHI
UDI-Device Identifier20612479202751
UDI-Public(01)20612479202751(17)260119(10)0000835806
Combination Product (Y/N)N
Initial Reporter StateGA
Initial Reporter CountryUS
PMA/510(K) Number
K993203
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 01/08/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date01/19/2026
Device Model NumberFHC-101
Device Catalogue Number5000
Device Lot Number0000835806
Was Device Available for Evaluation? Device Returned to Manufacturer
Is the Reporter a Health Professional? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 10/07/2024
Supplement Date Received by Manufacturer01/07/2025
Initial Report FDA Received Date10/22/2024
Supplement Report FDA Received Date01/08/2025
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured01/21/2024
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient Age19 YR
Patient SexFemale
Patient Weight72 KG
-
-